4D Molecular Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview

4D Molecular Therapeutics

06/05/2024 13:10

* 4D Molecular Therapeutics Inc  FDMT.OQ   FDMT.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 8 (estimated) for the period ending March 31 2024
    * The Emeryville California-based  company is expected to
report a
163.4% increase in revenue to $785 thousand from $298 thousand a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for 4D Molecular
Therapeutics Inc
is for a loss of 74 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.9%
in the last three months. ​
    * Wall Street's median 12-month price target for 4D
Molecular
Therapeutics Inc is $45.00​, above​ its last closing price
of $26.38. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.73       -0.74      -0.75     Missed  -1.2
 Sep. 30 2023  -0.66       -0.59      -0.24     Beat    59.6
 Jun. 30 2023  -0.80       -0.81      -0.77     Beat    4.7​
 Mar. 31 2023  -0.90       -0.89      -0.88     Beat    1.6
 ​​Dec.        -0.83       -0.79      -0.84     Missed  -6.9
 31 2022                                                
 Sep. 30 2022  -0.88       -0.91      -0.79     Beat    13.4​
 Jun. 30 2022  -0.87       -0.85      -0.87     Missed  -2.4
 Mar. 31 2022  -0.78       -0.81      -0.82     Missed  -1.2
 This summary was machine generated May 6 at 12:10 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)